Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

762
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
762
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

442
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
442
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

347
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
347
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

505
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
505
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

263
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
263
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

270
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
270

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kappa opioid receptor availability in borderline personality disorder: An in-vivo investigation with [<sup>11</sup>C]EKAP PET imaging.

Biological psychiatry·2026
Same author

The response of human melanocytic nevi to simulated solar radiation assessed by single-nucleus RNA sequencing of frozen tissue.

The Journal of investigative dermatology·2026
Same author

Widespread synaptic density loss in schizophrenia follows molecular and network architecture.

Molecular psychiatry·2026
Same author

Spectral EEG-guided adaptive neuromodulation for social anxiety disorder, performance-only subtype: a case report.

Frontiers in psychiatry·2026
Same author

Lower Muscarinic M1 Receptor Availability in Schizophrenia: In Vivo PET Evidence.

Biological psychiatry·2026
Same author

Psychotic Features in Myhre Syndrome: Evidence for Broader Neuropsychiatric Surveillance.

American journal of medical genetics. Part C, Seminars in medical genetics·2026

Related Experiment Video

Updated: Oct 20, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.1K

Selective Serotonin Reuptake Inhibitors: How Long Is Long Enough?

Robyn P Thom, Jeanne L Alexander, David Baron

    Journal of Psychiatric Practice
    |September 16, 2021
    PubMed
    Summary

    Selective serotonin reuptake inhibitors (SSRIs) offer relapse prevention for psychiatric conditions. Long-term use has low general risks but requires active monitoring for benefits and potential adverse effects like tachyphylaxis.

    More Related Videos

    Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
    12:21

    Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

    Published on: November 27, 2016

    15.3K
    The Forced Swim Test as a Model of Depressive-like Behavior
    05:42

    The Forced Swim Test as a Model of Depressive-like Behavior

    Published on: March 2, 2015

    38.3K

    Related Experiment Videos

    Last Updated: Oct 20, 2025

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
    08:20

    MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

    Published on: August 11, 2015

    14.1K
    Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
    12:21

    Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram

    Published on: November 27, 2016

    15.3K
    The Forced Swim Test as a Model of Depressive-like Behavior
    05:42

    The Forced Swim Test as a Model of Depressive-like Behavior

    Published on: March 2, 2015

    38.3K

    Area of Science:

    • Psychiatry
    • Pharmacology
    • Clinical Medicine

    Background:

    • Selective serotonin reuptake inhibitors (SSRIs) are first-line treatments for major depressive disorder and anxiety disorders.
    • Short-term SSRI use guidelines are available, but long-term management guidance is lacking.
    • SSRIs offer advantages in ease of titration, tolerability, and safety.

    Purpose of the Study:

    • To discuss the benefits and adverse consequences of long-term SSRI use.
    • To provide clinical practice considerations for chronic SSRI prescribing.
    • To highlight the need for active, periodic reassessment of long-term SSRI therapy.

    Main Methods:

    • Literature review and clinical practice discussion.
    • Analysis of benefits, risks, and management strategies for chronic SSRI use.
    • Focus on relapse prevention and adverse event monitoring.

    Main Results:

    • The primary benefit of long-term SSRI use is relapse prevention.
    • General health risks associated with long-term SSRI use appear low.
    • Long-term use may increase risks of tachyphylaxis and discontinuation syndrome.

    Conclusions:

    • Long-term SSRI use requires careful consideration of benefits versus risks.
    • Active, shared decision-making between patient and prescriber is crucial for long-term SSRI management.
    • Periodic monitoring is essential to reassess efficacy, safety, and tolerability.